Clinical Trial Update: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study [Phase 3]

View source ↗

Summary

This document reports an extension and crossover study of an RSV vaccine in adults 60 years and older who participated in a prior RSV trial; the Phase 3 study r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV vaccine (respiratory syncytial virus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING